ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NXL / earnings
NUWE (33) VBIO (36) NDRA (36) IRIX (27) ⌘ Pro Terminal →

Nexalin Technology Inc. (NXL) Next Earnings Date & Expected ±12.5% Move

$1.51 -5.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.49

Nexalin Technology Inc. (NXL) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NXL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NXL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nexalin Technology Inc. (NASDAQ: NXL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.51 (-5.94% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NXL ranks #747 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NXL compare to NUWE and VBIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NXL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, NUWE (Nuwellis Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and VBIO (Valion Bio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M). Among the 5-stock peer group, NXL leads on earnings multiple (N/A) while NXL leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NXL?
▼

Per NXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001527352), Nexalin Technology Inc. generated $301.6K in revenue (+78.8% YoY), -$8.2M in net income, and -$5.0M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.49 (-1.26%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (3)SEC (11)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.9% Base Target
$47 Bull$1 Base$1 Bear
📬 FREE NXL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NXL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY NXL SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 26.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$2.64-18.9% Next Q
Q2 (-2Q)
37
Grade E$2.14-23.4% Next Q
Q3 (-1Q)
35
Grade E$1.64-7.9% Next Q
Current
32
Grade E$1.51-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NXL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NXL currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.29) and Max Pain ($1.59) forces dealer call-delta covering toward $47.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NXL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NXL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.19 Expected Swing
$1.32 (-12.5%)Spot $1.51$1.70 (+12.5%)
MODEL EARNINGS SETUP GAUGE

NXL Quantitative Pre-Earnings Setup: 32/100

Trailing EPS: $4.25 • YoY Revenue Growth: 78.8%

Model Bullish Setup (32/100)Model Risk Weight (68/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$301.6K-$8.2M-$5.0M79.7%
FY 20242024-12-31$168.7K-$7.6M-$3.9M78.3%
FY 20232023-12-31$110.7K-$4.6M-$3.8M79.7%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NXL)

  • ✓Walkthrough of NXL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NXL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -86.75%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.63H $1.63L $1.51C $1.51VOL 21.2K
RES: $8.76SUP: $1.37SMA50: $4.29SMA200: $10.71
$25.80$19.22$12.63$6.05$-0.53RES $8.76SUP $1.37$1.512026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NXL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NXL Butterfly Map → + Track NXL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +78.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NXL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NXL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NXL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NXL)

Health Care Rank #747 of 1015 ⚔️ NUWE vs NXL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NXL vs. NUWE, VBIO, NDRA, IRIX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nexalin Technology Inc. (NXL) ranks #747 by composite RQD confidence (32/100, grade E) and #998 by equity capitalization ($1.8M). Within this direct 5-issuer industry benchmark cohort, NXL leads on earnings valuation at N/A trailing P/E, while NXL leads on capital efficiency and profitability with -35.0% ROIC and 79.7% gross margin. VBIO currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with NXL at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NXL ACTIVE
Nexalin Technology Inc.
E 32/100 — 79.7% -35.0% -5.94% $1.8M Benchmark Subject
NUWE
Nuwellis Inc.
E 33/100 — 62.0% -35.0% -8.80% $2.3M /nuwe-vs-nxl →
VBIO
Valion Bio Inc.
D- 36/100 — — -35.0% -3.47% $1.2M /vbio-vs-nxl →
NDRA
ENDRA Life Sciences Inc.
D- 36/100 — — -35.0% +1.05% $7.1M /ndra-vs-nxl →
IRIX
IRIDEX Corporation
E 27/100 — 36.5% -35.0% +1.33% $12.5M /irix-vs-nxl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001527352 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nexalin Technology Inc. (NXL) reported GAAP revenue of $301.6K (+78.8% vs. FY2024 revenue of $168.7K , and +172.4% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$5.0M, and free cash flow of -$5.0M (-25.7% YoY). On the balance sheet, NXL closed FY2025 with $4.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $301.6K -$8.2M -$5.0M -$5.0M $4.6M —
FY2024 (FY) 2024-12-31 $168.7K -$7.6M -$3.9M -$3.9M $4.2M —
FY2023 (FY) 2023-12-31 $110.7K -$4.6M -$3.8M -$3.8M — —

3. NXL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NXL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nexalin Technology Inc. (NASDAQ: NXL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.51 (-5.94% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, NXL ranks #747 in composite RQD confidence.

How does NXL compare to NUWE and VBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NXL carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, NUWE (Nuwellis Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and VBIO (Valion Bio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M). Among the 5-stock peer group, NXL leads on earnings multiple (N/A) while NXL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NXL?

Per NXL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001527352), Nexalin Technology Inc. generated $301.6K in revenue (+78.8% YoY), -$8.2M in net income, and -$5.0M in free cash flow against $4.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NXL trading relative to its 50-day, 200-day, and 52-week technical levels?

NXL last traded at $1.51 (-5.94% on volume of 11,870 shares), positioning the stock -64.80% below its 50-day simple moving average ($4.29) and -85.90% below its 200-day simple moving average ($10.71). Across its 52-week range of $1.51 to $45.00, NXL sits at the 0.0% percentile with a 14-day RSI of 26.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.32 to $1.70).

Direct Sub-Reports: NXL RQD Cockpit NXL 12M Forecast NXL Earnings & Move NXL Dividends & DRIP NXL Insiders & 13F NXL Whale Options NXL Profit Sankey NXL News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

NXL — Nexalin Technology Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nexalin Technology Inc. (NXL) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.51 (-5.94% 1D, market capitalization $1.8M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 79.7%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

And profile, Nexalin Technology Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Revenue is small, reported as $0.3M for FY 2025. The profile does not describe its products, customers, or specific revenue model. Gross margin is reported at 79.7%, while operating margin is -60%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nexalin Technology Inc. (NXL) reported $301.6K in annual revenue (up from $168.7K in FY2024, +78.8% YoY) and -$8.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($110.7K revenue, -$4.6M net income) through FY2025, NXL scaled operating cash flow to -$5.0M and free cash flow to -$5.0M, backed by $4.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.51 – $45.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), NXL carries a macro regime beta of 1.00 and gross margin of 79.7%.

  • Key Question #1: Can NXL sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $301.6K and free cash flow of -$5.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NXL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NXL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nexalin Technology Inc. (NXL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NXL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NXL Bull vs. Bear Conversation Board — What's Your Call at $1.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NXL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NXL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.97 (+23.1%)
📌 Pinned Debate

The company regained Nasdaq minimum bid price compliance and received a continued-listing grant from a Nasdaq Hearings Panel.

The street is overcomplicating Nexalin Technology Inc. (NXL). The company regained Nasdaq minimum bid price compliance and received a continued-listing grant from a Nasdaq Hearings Panel.. With an RQD score of 32/100 (E) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.73.

ArenaChamp_24 🐂 BULL

@DeepValue_CFA Agree on the RQD 32/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.60 and keeping dry powder in case we test $1.49.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.34 (-16.3%)
Spot @ $1.60

Operating losses of -$8.4M on $0.3M revenue in FY 2025, with ROIC at -35% and FCF yield at 0%, against cash of $0.7M.

Careful chasing NXL at $1.60. Operating losses of -$8.4M on $0.3M revenue in FY 2025, with ROIC at -35% and FCF yield at 0%, against cash of $0.7M.. Gross margin is 79.7%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.34 on multiple compression.

LIVE TAPE